<p>Reynders McVeigh Capital Management LLC 在第二季度购买了 Novo Nordisk A/S（纽约证券交易所代码：NVO - 免费报告）的新股份，根据其最近向证券交易委员会的备案。该基金购买了 363,889 股公司股票，价值约为 25,116,000 美元。</p>
<p>获取 <strong>Novo Nordisk A/S</strong> 警报：</p>
<ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
<p>其他机构投资者和对冲基金也调整了对该公司的持股。Revolve Wealth Partners LLC 在第四季度将其在 Novo Nordisk A/S 的持股增加了 8.7%。Revolve Wealth Partners LLC 目前拥有 2,490 股公司股票，价值 214,000 美元，此前在上个季度又购买了 200 股。Charles Schwab Investment Management Inc. 在第一季度将其在 Novo Nordisk A/S 的持股增加了 15.6%。Charles Schwab Investment Management Inc. 目前拥有 261,243 股公司股票，价值 18,141,000 美元，此前在该期间又收购了 35,329 股。Kovitz Investment Group Partners LLC 在第一季度将其在 Novo Nordisk A/S 的持股增加了 7.5%。Kovitz Investment Group Partners LLC 目前拥有 74,182 股公司股票，价值 5,151,000 美元，此前在上个季度又收购了 5,194 股。Horizon Investments LLC 在第一季度将其在 Novo Nordisk A/S 的持股增加了 117.4%。Horizon Investments LLC 目前拥有 5,466 股公司股票，价值 380,000 美元，此前在上个季度又购买了 2,952 股。最后，Aberdeen Group plc 在第一季度将其在 Novo Nordisk A/S 的持股增加了 7.9%。Aberdeen Group plc 目前拥有 280,734 股公司股票，价值 19,494,000 美元，此前在上个季度又购买了 20,565 股。目前，11.54% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师评级调整</h2>
<p>几位分析师最近对 NVO 股票发表了看法。Zacks Research 在 12 月 3 日的研究报告中将 Novo Nordisk A/S 的评级从 “持有” 下调至 “强烈卖出”。Jefferies Financial Group 在 10 月 27 日的研究报告中开始覆盖 Novo Nordisk A/S，并对该公司给予了 “表现不佳” 的评级。Sanford C. Bernstein 在 9 月 9 日的报告中将 Novo Nordisk A/S 的评级从 “市场表现” 上调至 “跑赢大盘”。TD Cowen 在 8 月 19 日的报告中将 Novo Nordisk A/S 的目标价从 105.00 美元下调至 70.00 美元，并对该股票给予了 “买入” 评级。最后，摩根士丹利在 11 月 28 日的报告中将 Novo Nordisk A/S 的目标价从 60.00 美元下调至 54.00 美元，并对该公司给予了 “买入” 评级。一位投资分析师对该股票给予了强烈买入评级，六位分析师给予了买入评级，十二位分析师给予了持有评级，三位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，共识目标价为 53.33 美元。</p>
<ul>
<li>HIMS 的股价波动不定。投资者应该入场吗？</li>
</ul>
<p><strong>获取我们对 NVO 的最新分析</strong></p>
<h2>Novo Nordisk A/S 股票下跌 0.3%</h2>
<p>NVO 股票在周一开盘价为 50.12 美元。该公司的速动比率为 0.57，流动比率为 0.78，债务与股本比率为 0.52。该公司的市值为 2,237.9 亿美元，市盈率为 14.57，贝塔值为 0.67。该股票的 50 日移动平均线为 50.86 美元，200 日移动平均线为 58.29 美元。Novo Nordisk A/S 的 12 个月低点为 43.08 美元，12 个月高点为 109.88 美元。</p>
<ul>
<li>年初至今下跌 45%，Novo Nordisk 引发价格战</li>
</ul>
<p>Novo Nordisk A/S（纽约证券交易所代码：NVO - 获取免费报告）最近于 11 月 5 日发布了季度财报。该公司报告每股收益为 1.02 美元，超出分析师共识预期的 0.77 美元，超出幅度为 0.25 美元。Novo Nordisk A/S 的净利润率为 32.76%，股本回报率为 73.50%。该公司季度收入为 117.9 亿美元，而分析师预期为 119.8 亿美元。卖方分析师预计 Novo Nordisk A/S 本财年将发布 3.84 美元的每股收益。</p>
<h2>Novo Nordisk A/S 公司简介</h2>
<p>（免费报告）</p>
<p>Novo Nordisk A/S 及其子公司从事药品的研究与开发、制造和分销业务，覆盖欧洲、中东、非洲、中国大陆、香港、台湾、北美及国际市场。它分为两个部门，分别是糖尿病与肥胖护理和罕见疾病。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Novo Nordisk A/S</li>
<li>S&amp;P/TSX 指数是什么？</li>
<li>3 只被低估的机器人股票，准备迎来巨额收益</li>
<li>2022-2025 年股市假期 - 纽约证券交易所和纳斯达克将关闭的时间</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入实施阶段</li>
<li>市盈率计算：如何评估股票</li>
<li>3 只在 10 年期国债收益率上升时值得购买的金融股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Novo Nordisk A/S 吗？</h2>
<p>在考虑投资 Novo Nordisk A/S 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Novo Nordisk A/S 并不在名单上。</p>
<p>虽然 Novo Nordisk A/S 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票的详细信息</p>

诺和诺德公司

<p>Reynders McVeigh Capital Management LLC 在第二季度收购了 363,889 股诺和诺德公司（Novo Nordisk A/S），价值 25,116,000 美元。机构投资者持有该股票的 11.54%。分析师的评级各不相同：一项 “强力买入”，六项 “买入”，十二项 “持有”，三项 “卖出”。该股票开盘价为 50.12 美元，市值为 2,237.9 亿美元。诺和诺德公司报告第三季度每股收益为 1.02 美元，超出预期 0.25 美元，收入为 117.9 亿美元</p>

<p>Reynders McVeigh Capital Management LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 2nd quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The fund bought 363,889 shares of the company's stock, valued at approximately $25,116,000.</p>
<div class="lb-trans"><p>Reynders McVeigh Capital Management LLC 在第二季度购买了 Novo Nordisk A/S（纽约证券交易所代码：NVO - 免费报告）的新股份，根据其最近向证券交易委员会的备案。该基金购买了 363,889 股公司股票，价值约为 25,116,000 美元。</p>
</div><p>Get <strong>Novo Nordisk A/S</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Novo Nordisk A/S</strong> 警报：</p>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p>Other institutional investors and hedge funds have also modified their holdings of the company. Revolve Wealth Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after purchasing an additional 200 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Novo Nordisk A/S by 15.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 261,243 shares of the company's stock valued at $18,141,000 after acquiring an additional 35,329 shares during the period. Kovitz Investment Group Partners LLC increased its stake in Novo Nordisk A/S by 7.5% in the first quarter. Kovitz Investment Group Partners LLC now owns 74,182 shares of the company's stock valued at $5,151,000 after acquiring an additional 5,194 shares during the last quarter. Horizon Investments LLC lifted its stake in Novo Nordisk A/S by 117.4% during the first quarter. Horizon Investments LLC now owns 5,466 shares of the company's stock worth $380,000 after purchasing an additional 2,952 shares during the last quarter. Finally, Aberdeen Group plc boosted its holdings in shares of Novo Nordisk A/S by 7.9% in the 1st quarter. Aberdeen Group plc now owns 280,734 shares of the company's stock valued at $19,494,000 after purchasing an additional 20,565 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金也调整了对该公司的持股。Revolve Wealth Partners LLC 在第四季度将其在 Novo Nordisk A/S 的持股增加了 8.7%。Revolve Wealth Partners LLC 目前拥有 2,490 股公司股票，价值 214,000 美元，此前在上个季度又购买了 200 股。Charles Schwab Investment Management Inc. 在第一季度将其在 Novo Nordisk A/S 的持股增加了 15.6%。Charles Schwab Investment Management Inc. 目前拥有 261,243 股公司股票，价值 18,141,000 美元，此前在该期间又收购了 35,329 股。Kovitz Investment Group Partners LLC 在第一季度将其在 Novo Nordisk A/S 的持股增加了 7.5%。Kovitz Investment Group Partners LLC 目前拥有 74,182 股公司股票，价值 5,151,000 美元，此前在上个季度又收购了 5,194 股。Horizon Investments LLC 在第一季度将其在 Novo Nordisk A/S 的持股增加了 117.4%。Horizon Investments LLC 目前拥有 5,466 股公司股票，价值 380,000 美元，此前在上个季度又购买了 2,952 股。最后，Aberdeen Group plc 在第一季度将其在 Novo Nordisk A/S 的持股增加了 7.9%。Aberdeen Group plc 目前拥有 280,734 股公司股票，价值 19,494,000 美元，此前在上个季度又购买了 20,565 股。目前，11.54% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several analysts recently weighed in on NVO shares. Zacks Research downgraded Novo Nordisk A/S from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Wednesday, December 3rd. Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a research report on Monday, October 27th. They issued an &#34;underperform&#34; rating for the company. Sanford C. Bernstein upgraded Novo Nordisk A/S from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a report on Tuesday, September 9th. TD Cowen reduced their target price on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, August 19th. Finally, The Goldman Sachs Group decreased their price objective on Novo Nordisk A/S from $60.00 to $54.00 and set a &#34;buy&#34; rating for the company in a report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of &#34;Hold&#34; and a consensus price target of $53.33.</p>
<div class="lb-trans"><p>几位分析师最近对 NVO 股票发表了看法。Zacks Research 在 12 月 3 日的研究报告中将 Novo Nordisk A/S 的评级从 “持有” 下调至 “强烈卖出”。Jefferies Financial Group 在 10 月 27 日的研究报告中开始覆盖 Novo Nordisk A/S，并对该公司给予了 “表现不佳” 的评级。Sanford C. Bernstein 在 9 月 9 日的报告中将 Novo Nordisk A/S 的评级从 “市场表现” 上调至 “跑赢大盘”。TD Cowen 在 8 月 19 日的报告中将 Novo Nordisk A/S 的目标价从 105.00 美元下调至 70.00 美元，并对该股票给予了 “买入” 评级。最后，摩根士丹利在 11 月 28 日的报告中将 Novo Nordisk A/S 的目标价从 60.00 美元下调至 54.00 美元，并对该公司给予了 “买入” 评级。一位投资分析师对该股票给予了强烈买入评级，六位分析师给予了买入评级，十二位分析师给予了持有评级，三位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，共识目标价为 53.33 美元。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 的股价波动不定。投资者应该入场吗？</li>
</ul>
</div><p><strong>Get Our Latest Analysis on NVO</strong></p>
<div class="lb-trans"><p><strong>获取我们对 NVO 的最新分析</strong></p>
</div><h2>Novo Nordisk A/S Stock Down 0.3%</h2>
<div class="lb-trans"><h2>Novo Nordisk A/S 股票下跌 0.3%</h2>
</div><p>NVO stock opened at $50.12 on Monday. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $223.79 billion, a PE ratio of 14.57 and a beta of 0.67. The stock's 50 day moving average is $50.86 and its 200-day moving average is $58.29. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $109.88.</p>
<div class="lb-trans"><p>NVO 股票在周一开盘价为 50.12 美元。该公司的速动比率为 0.57，流动比率为 0.78，债务与股本比率为 0.52。该公司的市值为 2,237.9 亿美元，市盈率为 14.57，贝塔值为 0.67。该股票的 50 日移动平均线为 50.86 美元，200 日移动平均线为 58.29 美元。Novo Nordisk A/S 的 12 个月低点为 43.08 美元，12 个月高点为 109.88 美元。</p>
</div><ul>
<li>Down 45% Year-to-Date, Novo Nordisk Ignites a Price War</li>
</ul>
<div class="lb-trans"><ul>
<li>年初至今下跌 45%，Novo Nordisk 引发价格战</li>
</ul>
</div><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Novo Nordisk A/S（纽约证券交易所代码：NVO - 获取免费报告）最近于 11 月 5 日发布了季度财报。该公司报告每股收益为 1.02 美元，超出分析师共识预期的 0.77 美元，超出幅度为 0.25 美元。Novo Nordisk A/S 的净利润率为 32.76%，股本回报率为 73.50%。该公司季度收入为 117.9 亿美元，而分析师预期为 119.8 亿美元。卖方分析师预计 Novo Nordisk A/S 本财年将发布 3.84 美元的每股收益。</p>
</div><h2>Novo Nordisk A/S Company Profile</h2>
<div class="lb-trans"><h2>Novo Nordisk A/S 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p>
<div class="lb-trans"><p>Novo Nordisk A/S 及其子公司从事药品的研究与开发、制造和分销业务，覆盖欧洲、中东、非洲、中国大陆、香港、台湾、北美及国际市场。它分为两个部门，分别是糖尿病与肥胖护理和罕见疾病。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Novo Nordisk A/S</li>
<li>What is the S&amp;P/TSX Index?</li>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Novo Nordisk A/S</li>
<li>S&amp;P/TSX 指数是什么？</li>
<li>3 只被低估的机器人股票，准备迎来巨额收益</li>
<li>2022-2025 年股市假期 - 纽约证券交易所和纳斯达克将关闭的时间</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入实施阶段</li>
<li>市盈率计算：如何评估股票</li>
<li>3 只在 10 年期国债收益率上升时值得购买的金融股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Novo Nordisk A/S 吗？</h2>
</div><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Novo Nordisk A/S 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Novo Nordisk A/S 并不在名单上。</p>
</div><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Novo Nordisk A/S 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票的详细信息</p>
</div>

Reynders McVeigh Capital Management LLC 收购诺和诺德公司 $NVO 的新股